TLX
Telix Pharmaceuticals Limited American Depositary Shares
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more ownership
Funds ownership: 0% [Q3] → 0% (+0%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$22
32%
upside
Avg. target
$22
32%
upside
High target
$22
32%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
UBS Laura Sutcliffe 50% 1-year accuracy 1 / 2 met price target | 32%upside $22 | Buy Maintained | 27 Jan 2025 |
Financial journalist opinion
Based on 6 articles about TLX published over the past 30 days
Neutral
GlobeNewsWire
8 hours ago
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) cyclotron technology has been referenced for the first time with a United States (U.S.) Food and Drug Administration (FDA) approved product, with Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection).
Positive
Investopedia
1 week ago
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Shares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.
Neutral
GlobeNewsWire
1 week ago
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer.
Neutral
GlobeNewsWire
2 weeks ago
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company's lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil.
Neutral
GlobeNewsWire
2 weeks ago
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production.
Neutral
GlobeNewsWire
4 weeks ago
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix's lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer.
Neutral
GlobeNewsWire
1 month ago
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
MELBOURNE, Australia and INDIANAPOLIS, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA3 date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.
Neutral
GlobeNewsWire
1 month ago
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
MELBOURNE, Australia and INDIANAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Center in Miami, FL, is recruiting and dosing patients in the ProstACT Global Phase 3 trial1 of TLX591 for patients with advanced prostate cancer, as part of a wider United States (U.S.) roll-out.
Positive
Zacks Investment Research
1 month ago
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
Telix Pharmaceuticals Limited (TLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
1 month ago
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Telix Pharmaceuticals Limited (TLX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Charts implemented using Lightweight Charts™